Anita K Dunbier

List of Publications by Year
in descending order

37 papers	3,631 citations	257450 24 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	5106 citing authors

#	Article	IF	Citations
1	Variable expression quantitative trait loci analysis of breast cancer risk variants. Scientific Reports, 2021, 11, 7192.	3.3	6
2	Structure vs. Function of TRIB1â€"Myeloid Neoplasms and Beyond. Cancers, 2021, 13, 3060.	3.7	7
3	Increased gene expression variability in BRCA1-associated and basal-like breast tumours. Breast Cancer Research and Treatment, 2021, 189, 363-375.	2.5	3
4	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. Breast Cancer Research, 2021, 23, 95.	5.0	3
5	Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. Science Signaling, 2018, 11, .	3.6	46
6	Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. BMC Cancer, 2018, 18, 805.	2.6	65
7	A PAM50-Based Chemoendocrine Score for Hormone Receptorâ€"Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research, 2017, 23, 3035-3044.	7.0	28
8	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2270-2278.	1.6	96
9	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	5.0	8
10	Aromatase Inhibitor Resistance via Non-endocrine Signalling Pathways. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 169-190.	0.1	2
11	Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptorâ€"positive breast cancers. Breast Cancer Research, 2014, 16, 447.	5.0	25
12	Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptorâ€"Positive Breast Cancer and Their Relationship with Antiproliferative Response. Clinical Cancer Research, 2014, 20, 2485-2494.	7.0	39
13	Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 3962-3973.	7.0	19
14	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncology, The, 2013, 14, 1067-1076.	10.7	332
15	Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2783-2790.	1.6	557
16	Molecular Profiling of Aromatase Inhibitorâ€"Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance. Clinical Cancer Research, 2013, 19, 2775-2786.	7.0	119
17	Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Research, 2012, 14, R78.	5.0	38
18	New and translational perspectives of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 2011, 340, 137-141.	3.2	9

#	Article	IF	Citations
19	Recent data on intratumor estrogens in breast cancer. Steroids, 2011, 76, 786-791.	1.8	28
20	Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids, 2011, 76, 736-740.	1.8	48
21	ERÎ±-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer Discovery, 2011, 1, 338-351.	9.4	284
22	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitorâ€"Treated ER-Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 3005-3012.	7.0	31
23	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. Clinical Cancer Research, 2011, 17, 4948-4958.	7.0	58
24	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clinical Cancer Research, 2011, 17, 2024-2034.	7.0	88
25	Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 120-123.	2.1	69
26	ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1. PLoS Genetics, 2011, 7, e1001382.	3.5	47
27	Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptorâ€"Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology, 2010, 28, 1161-1167.	1.6	94
28	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 2010, 28, 1829-1834.	1.6	647
29	Progress in aromatase research and identification of key future directions. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 311-315.	2.5	4
30	A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. BMC Cancer, 2008, 8, 138.	2.6	13
31	Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue In vivo. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 855-863.	2.5	10
32	Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clinical Cancer Research, 2008, 14, 8019-8026.	7.0	220
33	Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer. Cancer Research, 2007, 67, 2480-2489.	0.9	114
34	N-Terminal E-Cadherin Peptides Act as Decoy Receptors for Listeria monocytogenes. Infection and Immunity, 2003, 71, 1580-1583.	2.2	19
35	Gastric Cancer: Inherited Predisposition. , 2002, , 253-258.		0
36	Hereditary diffuse gastric cancer. Advances in Cancer Research, 2001, 83, 55-65.	5.0	35

#	Article	IF	Citations
37	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	21.4	420